Hepion pharmaceuticals, inc. (CTRV)
Balance Sheet / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13
ASSETS
Current assets:
Cash

13,922

14,863

17,149

1,682

2,800

9,032

2,580

3,997

5,954

8,778

12,982

6,137

10,551

3,028

7,403

5,956

9,832

1,791

4,563

8,901

8,791

735

1,817

2,510

3

76

86

Prepaid expenses

465

320

240

230

135

123

146

151

108

158

210

421

306

585

491

669

685

928

681

460

59

158

164

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid insurance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

117

5

-

-

Total current assets

14,388

15,184

17,389

1,913

2,968

9,155

2,741

4,149

6,062

8,937

13,192

6,558

10,858

3,613

7,894

6,626

10,517

2,719

5,244

9,361

8,851

893

1,982

2,627

-

-

86

Property and equipment, net

57

57

64

65

32

37

41

46

56

61

67

71

79

73

80

71

77

82

81

86

62

55

14

15

-

-

-

Right-of-use assets

797

642

684

724

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

3,190

-

-

-

-

-

-

-

-

-

-

-

-

Goodwill

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

1,870

-

-

-

-

-

-

-

-

-

-

-

-

Deferred Financing Costs

-

-

-

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

127

127

140

127

127

127

131

139

73

61

63

68

68

68

69

51

51

51

51

51

51

55

4

-

-

-

-

Total assets

20,432

21,073

23,339

7,904

8,189

14,381

7,975

9,396

11,252

14,121

18,384

11,759

16,067

8,816

13,106

6,749

10,646

2,853

5,377

9,499

8,964

1,004

2,000

2,643

8

76

86

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

491

675

282

706

748

2,215

2,079

1,731

1,556

1,483

1,626

1,562

2,302

4,397

4,252

3,441

3,162

3,195

1,481

1,312

114

213

243

187

55

28

3

Accrued expenses

493

308

535

657

661

421

920

831

1,046

1,327

1,318

910

921

765

820

847

598

1,019

456

302

246

244

207

66

33

36

40

Short term debt, net of discount

-

-

-

832

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, current

266

191

190

190

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible debt

-

330

790

1,070

1,440

2,070

2,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of contingent consideration

-

-

-

-

-

946

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

-

-

-

-

-

-

-

-

-

-

-

-

Due to Synergy

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

6

5

54

132

83

Demand note payable to Synergy and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

354

202

100

Total current liabilities

1,251

1,505

1,798

3,456

2,849

5,653

4,999

2,563

2,603

2,810

2,944

2,473

3,224

5,162

5,083

4,288

3,760

4,215

1,938

1,615

360

464

458

259

498

398

227

Contingent consideration

2,430

2,520

2,640

2,690

2,590

2,359

3,220

3,140

3,380

3,439

3,410

4,490

3,325

3,325

3,320

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax liability

18

360

360

-

360

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax liability

-

-

-

360

-

360

360

360

896

1,269

1,269

1,269

1,269

1,269

1,269

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, non-current

540

461

502

543

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent liability

-

-

-

-

9

8

7

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative financial instruments, at estimated fair value-warrants

5

0

8

208

404

1,345

139

274

669

1,608

1,702

3,912

2,371

2,055

2,115

1,165

1,900

-

-

-

-

-

4,475

9,725

-

-

-

Total liabilities

4,247

4,846

5,310

7,259

6,214

9,726

8,726

6,344

7,549

9,128

9,326

12,145

10,190

11,812

11,789

5,454

5,661

4,215

1,938

1,615

360

464

4,934

9,985

-

-

227

Commitments and contingencies (Note 13)

-

-

-

-

-

0

-

0

-

0

0

-

-

0

0

-

-

-

0

-

-

-

0

-

-

-

0

Stockholders' Equity:
Convertible preferred stock

-

-

-

-

-

0

0

0

-

0

0

0

0

-

0

-

-

-

-

-

-

0

-

0

0

0

0

Common stock-$0.0001 par value per share; 120,000,000 shares authorized, 3,760,255 and 247,013 shares issued and outstanding at December 31, 2019 and 2018, respectively

0

0

0

2

0

1

1

8

0

7

7

6

6

5

3

2

2

2

2

2

2

2

1

1

0

0

0

Additional paid in capital

97,651

95,797

95,772

77,326

76,652

77,461

72,125

71,708

69,676

69,222

67,513

60,121

58,575

44,596

32,226

26,998

26,770

17,394

17,350

16,420

12,742

7,429

2,486

2,458

-0

-0

-0

Accumulated deficit

-83,185

-81,288

-79,468

-78,447

-76,463

-73,891

-73,734

-69,705

-67,014

-65,277

-59,503

-61,553

-53,934

-49,429

-44,612

-39,406

-35,488

-32,458

-27,613

-22,238

-14,840

-6,891

-5,421

-

-

-

-140

Deficit accumulated during development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,802

490

322

-

Total stockholders' equity

16,185

16,226

18,029

645

1,975

4,654

-751

3,051

3,703

4,992

9,057

-385

5,877

-2,996

1,317

1,295

4,984

-1,361

3,439

7,883

8,603

539

-2,933

-7,342

-489

-322

-140

Total liabilities and stockholders' equity

20,432

21,073

23,339

7,904

8,189

14,381

7,975

9,396

11,252

14,121

18,384

11,759

16,067

8,816

13,106

6,749

10,646

2,853

5,377

9,499

8,964

1,004

2,000

2,643

8

76

86

Series A
Convertible preferred stock

855

855

855

855

855

-

-

-

1,040

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series C
Convertible preferred stock

861

861

868

908

930

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-